Findings reveal a mechanistic basis for understanding how cancer-associated fibroblasts activated in the tumor microenvironment by PDGF can act to promote cancer metastasis, with implications for arresting this deadly process.
INTRODUCTION
Studies on metastasis have traditionally focused on properties of the malignant cells.
However, recent studies in tumor biology have demonstrated that the tumor microenvironment exerts major influence on tumor behavior, including the metastatic process (1) (2) (3) . Several inflammatory cell types of the tumor microenvironment have been shown to affect the metastatic capacity of the malignant cells (4) . Also, vascular characteristics, determined by properties of endothelial cells and pericytes, contribute to the formation of a more or less metastasis-permissive microenvironment (5) . Moreover, factors derived from cancer-associated fibroblasts (CAFs) have been shown to promote metastasis (6) .
CAFs constitute a functionally important component of tumor stroma in many types of cancer (7) (8) . Clinical data indicate that carcinomas with desmoplastic stroma, consisting of fibroblast cells and extracellular matrix, are associated with a poorer prognosis which is consistent with the idea that CAF-derived factors stimulate invasion and metastases.
Clinical associations between activated CAFs and metastasis have also been demonstrated through prognostic fibroblast-derived gene signatures, including the core serum response-signature derived from serum-stimulated fibroblasts and stroma-derived breast and lung cancer gene signatures (9) (10) (11) CAF-derived secreted proteins include growth factors, cytokines, chemokines, ECM proteins, proteases, protease inhibitors and lipid products, which may be involved in pro-invasive effect of CAFs (7) (8) . Production of these factors is generally induced by growth factors that activate and recruit CAFs. Growth factors linked to CAF activation include members of the TGF-beta and hedgehog families, and chemokines including CXCL14 and CCL3 (12) (13) (14) (15) . Author Manuscript Published OnlineFirst on December 14, 2012; DOI: 10.1158/0008-5472. CAN-12-1875 Members of the PDGF family have also been identified as key regulators of CAFs (16) (17) . Paracrine activation of PDGF receptors on fibroblasts acts as a potent signal for tumor stroma recruitment (18) (19) (20) . Anti-tumor effects have been demonstrated following targeting of stromal PDGF receptors (21) (22) . PDGF-activated fibroblasts have also been shown, in animal tumor models, to exert a negative influence on tumor drug uptake, presumably through effects on interstitial fluid pressure (23) (24) (25) (26) (27) .
Recent analyses of primary tumors have established that stromal PDGF receptor expression is associated with worse prognosis in breast and prostate cancer (28, 29) .
Similar findings have been made in studies of smaller series of colorectal cancer (21) . Collectively the studies demonstrate pro-migratory and -invasive effects of PDGFstimulated fibroblasts. Importantly, stanniocalcin 1 (STC1), a poorly characterized secreted and hypoxia regulated protein, was identified as a fibroblast-derived mediator of the PDGF-dependent stimulatory in vitro effects. Fibroblast-derived STC1 was also shown in animal studies to contribute to pro-metastatic effects of fibroblasts. 
MATERIAL AND METHODS

Culture cells and identification of PDGF ȕ-receptor expression
Colorectal tumor cell lines LIM1215, SW620, HT29 and HCT116, immortalized fibroblast BJhTERT and wild-type and STC1-/-MEFs were cultured in Dulbecco's modified Eagle medium (DMEM; Gibco Life Technologies) containing 1% heatinactivated fetal calf serum (FCS), 2 mM L-glutamine, penicillin (100 units/ml) and streptomycin (100 ng/ml) at 37ºC in a 5% CO 2 humidified atmosphere. Cells were stimulated with PDGFBB (Peprotech) for 5 min at 37°C, and the expression of PDGF ȕ-receptor and its activation were analyzed by Western blotting using a specific PDGF ȕ-receptor antibody (Cell Signaling) and an antibody against phospho-tyrosine (phospho-Y99, sc-7020, Santa Cruz). (+/+) and (-/-) MEFs were provided by Roger R. Reddel. These cells were derived from previously described wild type and knock out STC1 C57BL/6 mice (30). MEFs were used at low passages and without experimentally induced or spontaneous immortalization.
Co-culture assays with tumor colon cells and fibroblasts for migration and invasion assays
Colon cancer cells were co-cultured with PDGF-stimulated or non-stimulated fibroblasts on 8.0 μm pore Transwells (Costar, Corning Incorporated) without coating for migration assays, or coated with Matrigel matrix (BD Biosciences) for invasion assays. Prior to co-culture, epithelial cells were labeled with a molecular probe (Cell Tracker green CMFDA C2925, Invitrogen), according to the manufacturer's instructions, to distinguish them from fibroblasts. After 48 h, epithelial cells that had reached the lower surface of the filter were recovered by trypsin treatment and counted by fluorescence with WALLAC plate reader (excitation at 485nm; emission at 535nm) by interpolation using a standard curve. For migration and invasion studies with physical separation, stimulated or non-stimulated fibroblasts were seeded in the lower compartment of the Transwell and the labeled colon cells in the upper one.
RNA Isolation, cDNA Synthesis, qRT-PCR analyses and gene expression microarray
Analyses were performed largely using standard procedures. Details are given in Supplemental Information.
siRNA STC1 down-regulation in BJhTERT fibroblasts
BJhTERT cells were seeded under standard conditions and transfected with either control or STC1 siRNA (Dharmacon RNA Technologies) using DharmaFect transfection reagent (Dharmacon RNA Technologies) according to the manufacturer's instructions. The cells were then co-cultured with colon cells for invasion experiments as described above.
Colorectal cancer patients and tissue microarray construction
The tissue micro array was derived from a population-based cohort of 320 patients with CRC. Details about patients and technical aspects related to the generation of the Tissue microarray is provided in Supplemental Information. 
Analyses of STC1 expression in human colorectal cancer
Sense and antisense RNA probes were generated using the PCR primer sequences detailed in SI Methods. Labeled RNA probes were generated by in vitro transcription from PCR products in the presence of digoxigenin-UTP. For in situ hybridization, tissues were digested by Proteinase K (Roche) and incubated with digoxigenin-labeled RNA probe. High-stringency washing was performed after hybridzation, followed by detection of the bound probe by chromogenic anti-digoxigenin antibody immunohistochemistry. Blocking of various endogenous enzymes was performed throughout the entire process. and experiments were performed in DMEM (# 21969, Gibco) media with 1% or 10% FCS and penicillin/streptomycin antibiotics in standard conditions. CAFs were used at low passages (between 6 and 8) and without experimentally induced or spontaneous immortalization.
Establishment of primary colon cancer CAFs
Statistical analysis
All t-test were performed following evaluation of equality of variance or not with Levene's test. Two-tailed P-values 0.05 were considered statistically different. 
RESULTS
PDGF-activation of fibroblasts increases their ability of paracrine stimulation of colon cancer cell migration and invasion
The colon cancer cell lines, LIM1215, SW620,HT29 and HCT116 were initially characterized with regard to expression of PDGF ȕ-receptors and production of their PDGF ligands. As shown in Figure 1A Figure 1D) . A potent PDGF-dependent effect was also observed on LIM1215 invasion in co-culture experiments. This was demonstrated when the two cell types were cultured together in the upper chamber of the trans-well culture system ( Figure 1D ).
As shown above, SW620 and HCT116 cells produced high levels of PDGF (Supplemental Figure 1B) . Addition of exogenous PDGF ligand in co-cultured fibroblasts did not show a significant increase in the migration of HCT116 cells (Supplemental Figure 1E ). Invasion experiments were performed which analyzed invasion of SW620 cells when cultured with fibroblasts in the absence or presence of the AG1296 PDGF receptor tyrosine kinase inhibitor (31) . As shown in Figure 1E , SW620 cell invasion was significantly reduced upon PDGF receptor inhibition.
Together these experiments thus demonstrate PDGF-dependent paracrine pro-migratory and pro-invasive effects of fibroblasts on colon cancer cells.
STC1 contributes to the PDGF-induced paracrine stimulatory effects of fibroblasts on migration and invasion of colon cancer cells
To identify mediators involved in PDGF-dependent paracrine signaling between fibroblasts and colon cancer cells, the gene expression profile of non-stimulated and PDGF-stimulated BJhTERT fibroblasts was analyzed by microarray analysis (GEO Series accession number: GSE40720). Stanniocalcin 1 (STC1) was among the most upregulated genes encoding secreted factors (see GEO data set). This poorly characterized, secreted hypoxia-induced protein was recently linked to ovarian cancer (32) .
Furthermore, earlier studies have also linked this protein to progression of colorectal cancer (33, 34) although negative effect on pro-survival signaling pathways has also been observed (35) . stimulatory effect than the wild-type fibroblasts, but this difference was consistently smaller than that observed in the presence of PDGF ( Figure 2C ).
To obtain independent evidence for a role of STC1 in the paracrine pro-invasive effects of fibroblasts, siRNA experiments were performed using the BJhTERT fibroblasts. As shown in Figure 2F , down-regulation of STC1 dramatically reduced the pro-invasive effect of BJhTERT cells in co-cultures with LIM1215 cells.
Together these experiments thus identify STC1 as a previously un-recognized important mediator of PDGF-dependent paracrine effects of fibroblasts on cancer cell migration and invasion. In agreement with previous studies, PDGF ȕ-receptor expression was predominantly observed in the tumor stroma, whereas variable expression of STC1 was found both in tumor stroma and in malignant cells. When results from PDGF ȕ-receptor and STC1
analyses were combined, a significant positive association between stromal PDGF ȕ-receptor and stromal STC1 expression was detected (p = 0.032; Figure 3A and B).
Analyses of stroma abundance, based on ASMA IHC analyses, demonstrated that the STC1 expression was not correlated to stroma abundance (Supplemental Figure 3A) .
To substantiate these findings, STC1 expression in primary cultures of CAFs isolated from colon cancers was also analyzed. Induction of STC1 was also observed in these 
STC1-/-fibroblasts display reduced ability to support tumor growth in an ortothopic colon cancer model
A previously described orthotopic colon cancer model was employed to evaluate the importance of fibroblast-derived STC1 for metastasis (36) . In previous studies HCT116 cells have been shown to recapitulate critical features of colon cancer growth including invasion into the muscle layer, infiltration into lymphatic and blood vessels, and formation of distant metastases in, e.g., the liver and the lung (36) . 
tumors gave rise to poorly differentiated adenocarcinomas in both groups. They were highly cellular, including atypical cells with pleomorphic nuclei and multinucleated cells. Tumors also formed diffuse fronts that invaded the local normal colon (Supplemental Figure 4A and B) . 
Tumors derived from co-injection with STC1-/-fibroblasts display reduced ability to form distant metastasis
The lymphatic and hematogenous cancer cell dissemination was analyzed by macroscopic and microscopic examination of lymph nodes, peritoneum, diaphragm, pancreas, liver and lungs. Interestingly, there was a difference in the number of affected organs such that tumors derived from the STC1-/-group showed a significantly lower number of affected organs per mouse ( Figure 5A ). Characterization of the distant metastatic lesions also revealed that the foci in the STC-/-MEF group were significantly smaller than those in the control group ( Figure 5B ).
The potential relationship between dissemination and size of primary tumor was also analyzed. Tumors were divided into two groups based on size (50% cut off), regardless of experimental group. This analysis did not reveal significant differences between the 9 "small primary tumor-group" and the 8 "large primary tumor-group" with regard to number of organs affected per mouse, or average lesion size (Supplemental Figure 5A and B). Calculations of "metastatic index", relating the number of affected organs to the size of the primary tumors, also indicated a reduced metastatic potency of tumors from the STC -/-MEF group (Supplemental Figure 5C ).
Metastases were divided into groups of lesions formed through the peritoneal route (peritoneum and diaphragm), the lymphatic route (lymph nodes and pancreas) and the hematogenous route (liver and lungs). As shown in Supplemental Figure 6 , this analysis indicated that metastasis formation via all three routes, based on the size of foci, was reduced in the STC1-/-MEF group (Supplemental Figure 6A-6I ).
This analysis thus demonstrated that the STC1 status of co-injected fibroblasts determined metastatic behavior of orthotopically implanted colon cancer cells. 
STC1 status of fibroblasts affects lymph vessel density and vascular invasion in primary orthotopic tumors
The possibility that STC1 status affected vascular infiltration was evaluated.
Interestingly, the number and size of intravasated tumor emboli was significantly reduced in the STC1-/-MEF group (Figure 6A and B) . Neither of these parameters differed significantly when tumors were divided according to size (Supplemental Figure   7A and B).
Decreased lymphatic vessel density, evaluated by LYVE-1 immunohistochemistry, was also considered as a factor contributing to the reduced metastasis in the STC1-/-MEF group. A significant decrease of lymph vessel density was observed in primary tumors with STC1-/-MEFs (Supplemental. Figure 7C and D) . However, a significant difference in lymphatic vessel density was also observed when tumors were grouped based on size (Supplemental Figure 7E ), making it difficult to evaluate if the phenotype was secondary to the effect of STC1 on tumor size, or reflected a more direct relationship between STC1 and lymphangiogenesis.
These findings thus suggest that STC1 status of fibroblasts affects metastasis by regulating the intravasating ability of colon cancer cells.
Characterization of tumors with regard to EMT, cancer stem cell content and macrophage infiltration
The presence of cell displaying an EMT phenotype, the abundance of cancer stem cells However, the analyses of size-divided tumor groups also revealed differences macrophage density, and the differences between the experimental groups could thus be secondary to the generally smaller size STC-/-tumors, rather than a direct consequence of the fibroblast genotype.
Vimentin immunostaining, using an antibody specific for human vimentin, was used as an EMT cell marker. EMT was detected in 4 out of 9 tumors in the STC1 +/+ group. In contrast, no sample in the STC1 -/-MEF group showed vimentin expression (p = 0.053; Ȥ 2 test) ( Figure 6C ).
Together these analyses suggest that STC1 directly contributes to EMT which could be involved in the effects on metastasis to lymph nodes and distant organs. A series of other studies based on tumor tissue analyses have provided findings which support a role for STC1 in cancer progression and metastasis (32) (33) (34) 37) . Increased levels of circulating STC1 mRNA has also been associated with worse prognosis in lung cancer (38) The findings imply stromal STC1 as a pro-metastatic factor. Preliminary analyses of the prognostic significance of stromal STC1 expression, based on the in situ analyses, demonstrated no prognostic effect of stromal STC1 in a multivariate analyses including tumor stage (Supplemental Figure 3) . Surprisingly, univariate analyses indicated an association between high stromal STC1 and better prognosis (Supplemental Figure 3) These inconclusive analyses should be extended. Such studies should particularly explore STC1 expression in the invasive front of colorectal cancer. It should also be noted that the present analyses relied on in situ expression analyses of STC1, which might not reflect protein expression. This approach was selected because validation experiments, using various antibodies and cells with known STC1 expression status, failed to confirm specificity of the available antibodies. Future studies should also CAN-12-1875 address the possibility that the prognostic significance of stromal STC1 expression might be restricted to certain molecular subsets of colorectal cancer. The results from the animal experiments strongly support a stimulatory effect of fibroblast-derived STC1 on metastasis to lymph nodes and distant organs. An important topic for future studies will be to further describe the in vivo mechanism(s) that are most important for the pro-metastatic effects of STC1. Based on the co-culture experiments, it is likely that a pro-migratory and pro-invasive effect of STC1 contributes to the pro-metastatic in vivo results. Furthermore, the analyses of tumor tissue suggest that STC1 also enhances the ability of cancer cells to intravasate. The potential involvement of epithelial-mesenchymal transition in the STC1-dependent differences in metastasis should be further explored based on the preliminary findings of the present study (Figure 6 C) . In the present study, no major alterations in cell type composition of tumors from the two groups were observed. However, this issue should be revisited by expanded analyses of various subsets of additional t stromal cells, such as fibroblasts, pericytes and neutrophils. These future analyses should also consider recent studies which have implicated STC1, in non-cancer models, as a regulator of inflammation, macrophage mobility and vascular permeability (39) (40) (41) (42) earlier studies have also demonstrated that hypoxia, a pro-metastatic stimuli, also leads to up-regulation of STC1 (43) .
Tumors with wild-type fibroblasts were significantly larger than the tumors with STC-/-fibroblasts, and it could be suggested that the differences in metastasis burden between the two groups are secondary to differences in tumor size. However, it should be noted that when animals were divided according to size of primary tumor, no significant differences in metastasis number or size was detected. The lack of correlation between size of primary tumor and metastasis is also in agreement with clinical findings showing that size of the primary tumor is not a consistent risk factor for metastasis (44) .
According to preliminary results (data not shown), fibroblast-derived STC1 did not affect cancer cell proliferation in vitro. However, a potential indirect effect of STC1 on cancer cell proliferation should not be excluded since Ki-67 staining of human samples showed an association with STC1 expression levels (Fig. 3E) . Also, the results from the study of experimental tumors support an effect on proliferation, since a decrease in 
